Vimarsana
Biggest News Aggregation in the World

Page 18 - Prag News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prag Today - Breaking & Trending Today

Jettwings, new regional airline for northeast states, plans takeoff in Oct - Vimarsana News

Jettwings, new regional airline for northeast states, plans takeoff in Oct

Promoters plan Rs 100-cr investment in new service, say flights will provide better legroom and dynamic fares

Holabird announces Four-Day High-Grade Auction, June 15th-18t - Vimarsana News

Holabird announces Four-Day High-Grade Auction, June 15th-18t

After conducting a pair of smaller “specialty” auctions over the last few months, a href= http://www.holabirdamericana.com target= _blank

Holabird's huge 4-day High-Grade Auction, June 15-18, is named after the high-grade ore from 19th c. mining and assaying - Vimarsana News

Holabird's huge 4-day High-Grade Auction, June 15-18, is named after the high-grade ore from 19th c. mining and assaying

The sale features mining collectibles, railroadiana, numismatics, Native and general Americana, philatelic, bottles, stocks, bonds, sports, art and more.

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer - Vimarsana News

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

/PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical...

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer - Vimarsana News

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on...